Rating
Buy
Price target
$200
Previous
Implied upside
+48%

UBS analyst Karl Keirstead reiterated a Buy rating and $200.00 price target on Palantir Technologies (NASDAQ: PLTR).

“SUMMARY: Over the last two weeks we’ve both hosted a group of investors at Palantir’s NYC office (with CFO Dave Glazer and Chief Architect Akshay Krishnaswamy) and attended Palantir’s latest AIPCon conference in SF where we spoke with customers and partners.

While the stock has lagged in part due to investor concerns about competition (including from the AI research labs), we remain Buy-rated.

Meeting With Palantir. Three things stood out: 1.

The dominant investor question was about Palantir’s moat in light of “rivals” (OpenAI, Anthropic, Databricks, others) building teams of FDEs and talking about data semantic or business context layers (on the surface, sounding like Palantir’s ontology layer).

Palantir highlighted the complexity and depth of its operating system (going well beyond deploying LLMs and ingesting data) and its focus on driving operational outcomes and decisions.

Palantir argued that the LLMs are unlikely to have material success diversifying into the data layer.”

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Share

Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.